Myeloid Sarcoma: Extramedullary Relapse After Allogeneic Bone Marrow Transplant for Chronic Myelogenous Leukemia

Authors

Maria Gubbiotti, Department of Hematopathology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PAFollow
Alina Dulau Florea, MD, Department of Hematopathology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PAFollow
Renu Bajaj, PhD, Cytogenetics Laboratory, Departments of Pathology, Anatomy and Cell Biology, Thomas Jefferson University Hospital; Molecular Cytogenetics Laboratory, Department of Genetics, Yale University School of MedicineFollow

Document Type

Poster

Publication Date

4-26-2013

Abstract

Myeloid sarcoma (MS) is an extramedullary tumor of myeloid precursor cells, which can precede or occur concomitantly with acute myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasms. Although MS can involve any organ, it is more common in the central nervous system (CNS) and gonads, sites known as “pharmacologic sanctuaries” where leukemic cells can survive despite systemic chemotherapy. Less often, this tumor can be the manner of relapse after allogeneic bone marrow transplantation.

The diagnosis is based on morphology and immunophenotype by either flow cytometry or immunohistochemistry of paraffin-embedded tissue, and confirmed by FISH or molecular studies. Myeloid sarcomas usually express the leukocyte common antigens CD45, CD13, CD33, CD43 and lack T-cell and B-cell antigens.

Recommended Citation

Gubbiotti, Maria; Dulau Florea, MD, Alina; and Bajaj, PhD, Renu, "Myeloid Sarcoma: Extramedullary Relapse After Allogeneic Bone Marrow Transplant for Chronic Myelogenous Leukemia" (2013). Department of Pathology Honors Program Student Research Symposium. Poster 5.
https://jdc.jefferson.edu/phsrs/5